Week in Review: ShangPharma Partners to Build Biologics Campus

ShangPharma, a Shanghai CRO/CMO, will partner with Qidong Biopharma Industrial Zone to build a $60 million biologics campus, including R&D and manufacturing facilities; China's Tendcare Medical raised $40 million from Olympus Capital Asia to acquire more hospitals; Crystal Pharmatech, a Suzhou-New Jersey clinical research organization, secured $10 million in a Series A round led by China social media company Renren; Yabao Pharma (SHA: 600351) in-licensed greater China rights to a stroke treatment candidate from Primary Peptides of Vancouver; Jiangsu Hengrui Medicine will invest $240 million to build a biopharmaceutical production facility in Lianyungang; Veritas Genetics, a Boston diagnostics startup, established a China R&D center in the Hangzhou Economic & Technological Development Area; Beijing Shenogen Biomedical announced that Icaritin, a Class I cancer drug, was granted Fast Track Review in China; and ASLAN Pharma of Singapore received approvals to conduct a clinical Phase II trial in Singapore and Taiwan of its lead drug, which targets a form of liver cancer. More details.... Stock Symbol: (SHA: 600276) Share this with colleagues: // //